Xcout Intel
VitriVax
VitriVax, Inc. is a biotechnology company headquartered in Boulder, Colorado, dedicated to eliminating barriers to global vaccination. The company develops innovative vaccine formulation and stabilization technologies.
Subscribe to see VitriVax’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
VitriVax at a glance
VitriVax is a biotechnology company headquartered in United States. It has raised at least $46.7M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $17.3M in October 2025. Xcout tracks 10 named people at VitriVax, including Louise Brady (Chief Executive Officer).
VitriVax leadership
- Louise BradyChief Executive Officer
- Romulo ColindresPresident/CEO
- Rene LorenzCO-FOUNDER
- Theodore RandolphCo-Founder
- Romulo ColindresExecutive Officer
- Louise BradyDirector
4 more named people on record for VitriVax, with roles, board committees and tenure — see the full roster →
VitriVax funding rounds
At least $46.7M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $17.3M | 4 named | |
| SEC Form D filing | $29.4M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
VitriVax competitors
A few of VitriVax's closest competitors — see the full list of competitors and alternatives →
GlobeImmune, Inc. is a clinical-stage biopharmaceutical company headquartered in Louisville, Colorado, focused on developing therapeutic vaccines to treat cancer and infectious diseases.
Mosaic Biosciences, Inc. is a biotechnology company based in Boulder, Colorado. The firm operates research and corporate facilities to support scientific discovery and development.
Vaxxas is a clinical-stage biotechnology company headquartered in Brisbane, Australia. It is commercializing a novel vaccination technology designed to enhance the performance of existing and next-generation vaccines, and opened a biomedical manufacturing facility in Brisbane in June 2023.
MalarVx, Inc. is a clinical-stage biopharmaceutical vaccine company located in Seattle, Washington, founded to develop innovative vaccines addressing global infectious diseases.
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
Enveda Biosciences (Enveda Therapeutics Inc.) is a biotechnology research company headquartered in Boulder, Colorado. The company leverages artificial intelligence to discover novel therapeutics and chemical compounds derived from natural sources.
Get VitriVax's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on VitriVax in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access